Skip to main content
Premium Trial:

Request an Annual Quote

Moderna to Acquire Japan's OriCiro Genomics for $85M

NEW YORK – Messenger RNA vaccine and therapeutics maker Moderna said on Wednesday that it has entered into a definitive agreement to acquire Tokyo-based synthetic biology firm OriCiro Genomics for $85 million.

Other details of the deal were not disclosed.

"With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in messenger RNA (mRNA) manufacturing," Moderna CEO Stéphane Bancel said in a statement. "OriCiro's technology strategically complements our manufacturing expertise and further accelerates our research and development engine."

Founded in 2018 to develop and commercialize a technology for cell-free assembly and amplification of large circular DNA, OriCiro raised approximately $7.3 million in Series B funding in July 2021, led by University of Tokyo Edge Capital Partners. The firm expanded its Series B round in June 2022 by an undisclosed amount from Asahi Kasei Medical and opened a US office in Boston last year.

Moderna has been developing mRNA-based therapeutics and vaccines. Its COVID-19 vaccine, among others like it, helped prove the clinical efficacy of mRNA technology.

The OriCiro deal underscores Cambridge, Massachusetts-based Moderna's global ambitions. The firm struck a deal to build an mRNA vaccine manufacturing facility in the UK last June and has revealed plans to build facilities in Australia, Canada, and Kenya.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.